Why Methadone Still Matters
Methadone is the oldest, most studied, and, by the hardest outcome that matters, arguably the most effective medication we have for opioid use disorder. It is a full mu-opioid agonist that, taken once daily by mouth, occupies opioid receptors around the clock, abolishes withdrawal, blunts craving, and blocks the euphoria of illicit opioids by tolerance and cross-occupancy. In the era of fentanyl, that matters more than ever: methadone keeps people alive.
The core evidence is not subtle. Compared to no medication or to detoxification alone, methadone maintenance cuts all-cause mortality and overdose death by roughly half, keeps patients in treatment far longer than psychosocial approaches alone, and reduces illicit opioid use, injection, HIV transmission, and criminal involvement. Cohort after cohort, going back to the original Dole and Nyswander work in the 1960s, shows the same thing: the periods a person spends on an adequate methadone dose are the periods they are least likely to die.
Yet methadone is hemmed in by a regulatory apparatus that exists for no other psychiatric or medical drug in America. For opioid use disorder it can be dispensed only through federally certified opioid treatment programs (OTPs), the "methadone clinic," with daily observed dosing, gradually earned take-homes, and layers of state and federal oversight. The same molecule, prescribed for pain, can be written on an ordinary prescription pad by any DEA-registered clinician: a regulatory split that confuses everyone. Add a genuine pharmacologic hazard, a long, variable half-life that makes the first week of induction the single most dangerous stretch of treatment, plus QT-prolongation concerns, plus decades of stigma, and you have a drug that many capable clinicians never learn to use.
This guide is about using it well.
Methadone's danger is not the dose you give: it's the dose that accumulates over the following days. "Start low, go slow" is not conservatism. It is the difference between a patient who stabilizes and a patient who dies in their sleep on day 4.
The thesis throughout: methadone is one of the most life-saving drugs in medicine, and its dangers are almost entirely front-loaded into induction and almost entirely preventable if you respect its pharmacokinetics. Start low. Go slow. Understand that steady state lags dosing by five days or more, so the dose you feel good about on Tuesday can accumulate to a lethal level by Friday. Screen the QTc. Warn relentlessly about benzodiazepines and other sedatives. Do those things, and you have access to a treatment that returns chaotic, dying patients to stable lives.
How to Use Methadone With Confidence
Let's name the fears honestly, because they are the reason many clinicians refer methadone out rather than learn it. Each fear is legitimate. Each is also manageable with a system.
"I'm terrified of killing someone during induction."
You should take this seriously: induction deaths are real, and they cluster in the first one to two weeks. But the mechanism is completely understood, which makes it preventable. The problem is accumulation: methadone's half-life is long (typically 24–36 hours, sometimes far longer) and variable between people, so a fixed daily dose keeps building for four to five days before it plateaus. A patient can feel undertreated on day 1, get a dose increase, feel undertreated on day 2, get another increase, and then, on day 4 or 5, all of that accumulated drug reaches a peak that stops their breathing. The classic phrase is that most methadone induction deaths happen days 3 to 5, not day 1.
The system that prevents this is simple and non-negotiable:
Start at 10–30 mg on day 1. Federal rules cap the initial single dose at 30 mg and the total first-day dose at 40 mg for exactly this reason.
Do not chase full comfort on day 1. The goal of induction is to prevent severe withdrawal and buy time, not to eliminate every symptom. Residual mild withdrawal on day 1 is expected and safe; over-dosing to erase it is what kills.
Hold the dose steady and let it accumulate. Increase slowly, commonly no more than 5–10 mg every 3–5 days after the first few days, because you are always dosing "blind" to where steady state will land.
Titrate to the trough, not the peak. Assess the patient before their next dose (when the drug is at its lowest), not two hours after dosing (when it is at its highest). If they're comfortable at the trough, they have enough.
Internalize the rhythm: the effect you see today reflects a dose you gave several days ago. Once that clicks, induction stops being frightening and becomes a slow, deliberate climb.
"The QTc thing makes me nervous."
Methadone can prolong the QT interval and, rarely, cause torsades de pointes, mostly at higher doses and mostly in people with other risk factors. This is real but very manageable, and it should never be a reason to withhold a life-saving drug:
- Get a baseline ECG when feasible, especially with cardiac history, other QT-prolonging drugs, or electrolyte issues, and repeat it as the dose climbs (particularly above ~100 mg/day).
- Use the numbers. A QTc under 450 ms is reassuring. Between 450 and 500 ms, correct reversible causes (low potassium, low magnesium, interacting drugs) and monitor. Above 500 ms, weigh a dose reduction, address every contributor, and consider whether buprenorphine is the safer agent.
- Keep perspective. The absolute risk of torsades on methadone is low, and the mortality benefit of treatment is enormous. You manage the QTc the way you manage any monitorable risk: you don't abandon the drug over it.
"The OTP regulations are a black box."
The regulatory complexity is real, but it's a logistics problem, not a clinical one, and the clinic infrastructure exists precisely to carry that weight. For OUD, methadone lives inside a certified OTP: intake, observed daily dosing, counseling, and take-home privileges that are earned over time as the patient stabilizes. You do not have to build this yourself: you refer into it, or you work within it, and the program handles diversion controls, take-home schedules, and the state and federal paperwork. Your clinical job, inducing safely, dosing to an adequate level, screening the QTc, watching for interactions, is the same whether or not you love the paperwork. And remember: for chronic pain, none of the OTP machinery applies; methadone is an ordinary controlled-substance prescription.
"There's so much stigma, from staff, from families, even from me."
The stigma is the least evidence-based barrier of all. The data are unambiguous: agonist maintenance is more effective than any other single treatment for opioid dependence, and time off medication is when patients die. "Some methadone is better than no methadone" is a defensible clinical stance. A patient stable on methadone with a job and a family is not "still using" or "trading one addiction for another": they are in remission from a lethal disease, exactly as a diabetic on insulin is in remission. Say that out loud, to your patients and to yourself.
Methadone isn't dangerous because it's a full agonist. Methadone is safe because its one dangerous window, induction, is short, understood, and defended by a simple protocol. Respect the pharmacokinetics for two weeks, screen the QTc, hammer the benzodiazepine warning, and you are offering patients the single most life-saving option in addiction medicine.
Part 1: Indications: Who Is Methadone For?
Approved and established uses
- Opioid use disorder, maintenance treatment. The core indication and the reason methadone matters. Delivered through certified OTPs.
- Medically supervised opioid withdrawal (detoxification). Methadone can be used for withdrawal management, though maintenance consistently outperforms detox-only approaches on retention and survival.
- Chronic pain. As a potent long-acting opioid analgesic (this is where the "Dolophine" brand and ordinary-prescription pathway apply), used mainly by pain and palliative specialists, a role that demands its own expertise because of the same accumulation and QT risks.
Who is methadone especially for?
Methadone and buprenorphine are both first-line for OUD, and for many patients either works. Methadone earns the edge in specific situations:
- More severe or long-standing opioid use disorder, including high-tolerance patients using large amounts of fentanyl or heroin.
- Patients who have failed buprenorphine, either through inadequate craving control at the ceiling of the partial agonist, or through recurrent precipitated-withdrawal problems at induction.
- Patients who cannot tolerate the transition to buprenorphine. Because buprenorphine is a partial agonist with high receptor affinity, starting it too early precipitates withdrawal; methadone, a full agonist, can be started without that hurdle and is often easier to initiate in someone who cannot achieve the required abstinence window.
- Patients who do better with the structure of daily observed dosing: for some, the clinic scaffold is a feature, not a bug.
- Pregnancy, where methadone has the longest track record of safe use in OUD (see Special Populations).
Who is buprenorphine or naltrexone the better fit for?
- Buprenorphine for most patients who value office-based care and independence, and for anyone in whom the respiratory safety margin of a partial agonist is especially valuable.
- Naltrexone (oral or monthly injectable Vivitrol 380 mg IM) for the highly motivated patient who wants, or whose circumstances require, an antagonist-based, non-agonist approach, and who can complete a 7–10 day opioid-free washout first. Its real-world weakness is retention.
The best OUD medication is the one the patient will actually stay on. Retention is the outcome, because time in treatment is time alive. Match the drug to the patient's life, not to your comfort level.
Part 2: Before You Start: Workup and Candidacy
History and assessment
- Confirm opioid dependence and characterize it: which opioids, route, amount, duration, and, critically in the fentanyl era, likely tolerance.
- Full substance history, with special attention to benzodiazepines, alcohol, and other sedatives (the sources of the deadliest interactions) and to stimulants.
- Cardiac history: known arrhythmia, syncope, structural heart disease, family history of sudden death or long-QT syndrome.
- Concomitant medications, screening specifically for QT-prolonging drugs, CYP3A4 inducers/inhibitors, and other CNS depressants.
- Pregnancy status in anyone who could be pregnant.
- Hepatic and renal status (methadone is hepatically metabolized).
Baseline testing
| Test | Why |
|---|---|
| ECG (QTc) | Baseline for the drug's signature cardiac risk; essential with cardiac history, other QT drugs, or planned higher doses |
| Electrolytes (K⁺, Mg²⁺) | Low potassium/magnesium potentiate QT prolongation and torsades |
| Urine drug screen | Confirms recent opioid use; identifies benzodiazepines, stimulants, and other risks |
| LFTs | Baseline hepatic function (site of metabolism) |
| Pregnancy test (hCG) | Guides counseling and coordination with obstetrics |
| HIV / hepatitis screening | High-yield in this population; part of comprehensive care |
Do not let the perfect workup delay a life-saving induction, but the ECG and a basic sense of cardiac and interaction risk should inform how cautiously you dose.
Who needs extra caution?
- Prolonged baseline QTc (especially >450–500 ms) or high torsades risk: not an absolute bar, but demands care and often favors buprenorphine.
- Active heavy benzodiazepine, alcohol, or other sedative use: the highest-risk combination for fatal respiratory depression. This is a reason to intensify caution and counseling, not a reason to deny treatment (untreated OUD with fentanyl exposure is more dangerous still).
- Severe respiratory disease or sleep apnea.
- Significant hepatic impairment (altered metabolism and clearance).
- Low opioid tolerance: an opioid-naïve or low-tolerance patient is far more vulnerable to a full agonist; standard OUD induction doses can be dangerous here.
Part 3: How to Start and Dose
This is the part that saves lives or costs them. Read it twice.
The governing pharmacokinetics
- Half-life is long and highly variable: typically ~24–36 hours, and considerably longer in some people. Duration of analgesic action is much shorter (hours), which creates a trap: pain patients may feel the drug wear off long before it has cleared, tempting redosing that accumulates dangerously.
- Steady state is not reached for about 5 days (often longer) after starting or after any dose change. This means the full effect of today's dose won't be seen for days, and the drug keeps accumulating the whole time.
- Therefore: every dose you give is a partial picture. You are always dosing toward a plateau you cannot yet see.
Start low, go slow, and remember that steady state takes at least five days. The classic catastrophe is the "overdose in week 1": a patient dosed upward too quickly whose accumulating level peaks fatally on day 3 to 5. Patience is the safety mechanism.
Formulation
Oral is standard for OUD: liquid concentrate, dispersible tablets, or tablets, dispensed and usually observed at the OTP. Parenteral routes exist but are rarely used in maintenance.
Induction: the first days
- Day 1Start at 10–30 mg. Federal regulation caps the initial single dose at 30 mg and the total first-day dose at 40 mg, limits built specifically around accumulation risk. Choose the lower end for lower-tolerance patients, uncertain histories, or any concern about sedatives on board. An additional small dose later on day 1 may be given if significant withdrawal persists, staying within the day-1 cap. Aim to suppress severe withdrawal, not to achieve full comfort.
- Days 2–5Early titration is deliberately slow. Increase in small increments, on the order of 5–10 mg every 3–5 days, guided by trough symptoms, never faster than steady state can reveal the effect of what you've already given. This is the highest-risk window: accumulation peaks around days 3–5.
- Weeks 2+Typical stabilizing range emerges around 60–120 mg/day, reached over weeks, not days. Some patients need more; some need less. The dose is right when it holds the patient comfortably through to the next day's trough without oversedation.
Judge adequacy just before the next dose, when methadone is at its lowest. A patient who is comfortable at the trough is adequately dosed. Chasing comfort at the peak leads to accumulation and oversedation.
What "enough" looks like
An adequate maintenance dose does three things: abolishes withdrawal across the full 24 hours, suppresses craving, and, through tolerance and receptor occupancy, blunts the reward of illicit opioids. Underdosing is a leading cause of continued illicit use and dropout; the fix for craving-with-continued-use is usually more methadone (titrated carefully), not less. Effective maintenance doses are frequently in the ~80–120 mg/day range; don't strand a patient at a subtherapeutic 40–50 mg out of timidity once they're past the vulnerable induction window.
Watch for oversedation at every early visit
Before each dose increase, look for sedation, nodding, slurred speech, or pinpoint pupils. Sedation is the warning sign that accumulation is outrunning your titration. If present, hold or reduce; do not increase.
Part 4: Monitoring
During induction (highest-risk window)
- Assess for sedation and respiratory status at each early dosing contact, especially days 3–5 when accumulation peaks.
- Reinforce the induction warnings every visit: no benzodiazepines, no alcohol, no adding other sedatives, and no "topping up" with illicit opioids on top of the methadone.
The cardiac screen you can't skip: ECG and QTc
Methadone is one of the few psychiatric or addiction medications that genuinely requires cardiac vigilance. As the dose rises, so does the risk of QT prolongation and, rarely, torsades de pointes.
- Baseline ECG where feasible; prioritize it in patients with cardiac history, electrolyte issues, other QT-prolonging drugs, or planned higher doses.
- Repeat as the dose rises, with particular attention above ~100 mg/day, and after adding any interacting or QT-prolonging medication.
<450 ms: reassuring. 450–500 ms: correct reversible causes (low potassium, low magnesium, interacting drugs) and monitor. >500 ms: address every contributor and weigh dose reduction or a switch to buprenorphine.
Urine drug screens
Use them as a clinical tool, not a gatekeeper. Periodic screening (rather than punitive every-visit testing) tracks illicit opioid use, confirms methadone presence, and, critically, flags benzodiazepine, alcohol, or stimulant use that changes the risk picture.
A positive screen opens a conversation about dose adequacy and supports; it is not, by itself, grounds for discharge.
Ongoing
- Reassess dose adequacy (trough withdrawal, craving, ongoing use) and oversedation at each visit.
- Recheck electrolytes if the patient develops vomiting, diarrhea, or starts a drug that alters potassium/magnesium.
- Monitor hepatic status as clinically indicated.
Part 5: Side Effects and How to Manage Them
Most methadone side effects are the class effects of any opioid, are dose-related, and often ease with time and tolerance, with the important exceptions of constipation (which does not abate) and QT prolongation (which tracks with dose).
Sedation (especially early)
Most prominent during induction and after dose increases, and the key warning sign of accumulation.
Management: never increase into sedation. Hold or lower the dose; look hard for other sedatives (benzodiazepines, alcohol, sleep aids, gabapentinoids). Sedation that persists at a stable maintenance dose warrants a search for an interacting drug or another cause.
Respiratory depression
The lethal side effect, concentrated in induction and in combination with other CNS depressants. Covered in full under Overdose and Toxicity, but understand it is the thing you are titrating around.
Constipation
Nearly universal and, unlike most opioid effects, it does not resolve with tolerance.
Management: start a bowel regimen early: an osmotic laxative (e.g., polyethylene glycol) plus a stimulant laxative (senna, bisacodyl) as needed. Avoid bulk-forming agents like psyllium, which can worsen opioid constipation. Adequate fluid and activity help.
QT prolongation
Dose-dependent, occasionally leading to torsades. See Monitoring for the QTc thresholds and actions. Correct low potassium and magnesium, minimize other QT-prolonging drugs, and use the ECG to steer dosing.
Hypogonadism (a commonly missed chronic effect)
Long-term full-agonist opioid therapy suppresses the hypothalamic-pituitary-gonadal axis, causing low testosterone in men (low libido, fatigue, erectile dysfunction, reduced muscle mass, mood effects) and menstrual irregularity in women.
Management: ask about it; patients rarely volunteer it. Check morning testosterone in symptomatic men; involve endocrinology for replacement decisions. It is a genuine quality-of-life issue that undermines long-term adherence when ignored.
Sweating
Excessive sweating is common and can be quite bothersome.
Management: reassurance; consider a modest dose reduction if adequacy allows; symptomatic measures.
Other
- Nausea/vomiting: common early, usually settles with tolerance; symptomatic antiemetics if needed (be mindful that some antiemetics also prolong QT).
- Weight gain, edema, dry mouth, decreased libido: recognized longer-term effects.
- Miosis: expected; frank pinpoint pupils with sedation signal too much drug.
Part 6: Overdose and Toxicity: The Signature Danger
Methadone's defining hazard deserves its own section because its shape is unlike other opioids.
Why induction is uniquely dangerous
Short-acting opioids overdose you the day you take too much. Methadone can overdose you days after a dose that seemed fine, because of the same pharmacokinetics that make it a good maintenance drug:
- The long, variable half-life means the drug accumulates for ~5 days before plateauing.
- A dose that produces acceptable effect on day 1 keeps building, so the same daily dose yields a higher and higher blood level through the week.
- Tolerance builds more slowly than the level rises during rapid up-titration.
Most methadone induction deaths occur on days 3–5, not day 1, often overnight, as delayed, cumulative respiratory depression peaks during sleep. This is why the entire induction protocol is built around going slow and dosing to the trough.
Presentation of overdose
The opioid triad, depressed consciousness, respiratory depression (slow, shallow breathing), and pinpoint pupils, with the crucial methadone caveat that its onset can be delayed and its duration prolonged.
Management
Naloxone reverses it, but methadone outlasts naloxone. Because methadone's effect lasts far longer than a single dose of the antagonist, the patient can re-narcotize as naloxone wears off. Overdose requires prolonged observation and often repeated naloxone dosing or a naloxone infusion, never a single dose and discharge.
This is an emergency: airway, breathing, continuous monitoring, ED/critical care.
What precipitates toxicity
- Too-fast induction (the leading cause).
- CNS depressants: benzodiazepines, alcohol, other opioids, sedative-hypnotics, gabapentinoids.
- Low opioid tolerance relative to the dose (opioid-naïve patients, or return to a prior dose after a break in treatment; tolerance falls fast during any gap).
- Drug interactions that raise methadone levels (CYP3A4 inhibitors; see Drug Interactions).
The most dangerous patient is not the one on a high maintenance dose: it's the one being inducted, or the one restarting after missed doses. Tolerance vanishes within days of stopping; never resume a patient at their old dose after a gap. Re-induct from a low dose.
Part 7: Drug Interactions
Methadone's interactions fall into two buckets: those that add to CNS/respiratory depression (deadly) and those that change methadone levels via hepatic metabolism.
The black-box combination: benzodiazepines and other CNS depressants
- Mechanism: synergistic respiratory depression.
- Significance: the highest; this is the interaction that kills. Benzodiazepines, alcohol, other opioids, sedative-hypnotics, and gabapentinoids all stack with methadone's respiratory effect.
- Management: counsel relentlessly. Minimize or avoid benzodiazepines where possible. But apply the harm-reduction logic addiction medicine has settled on: do not reflexively withhold methadone from a patient who uses benzodiazepines. A patient on benzodiazepines plus street fentanyl is at higher risk than one on benzodiazepines plus a monitored methadone dose. Assess carefully, document your risk-benefit reasoning, work to reduce the sedative, and keep the patient in treatment.
Metabolism: CYP3A4 (primary) and CYP2D6
Methadone is metabolized in the liver, principally by CYP3A4 with contributions from CYP2D6 and other enzymes.
- CYP3A4 inducers LOWER methadone levels and risk withdrawal and craving. Classic culprits: rifampin, carbamazepine, phenytoin, phenobarbital, efavirenz and some other antiretrovirals, St. John's wort. A patient stabilized on methadone who starts an inducer can be thrown into withdrawal; you may need to raise the methadone dose and re-lower it if the inducer is stopped.
- CYP3A4 inhibitors RAISE methadone levels and risk sedation, accumulation, and QT prolongation. Culprits include azole antifungals (ketoconazole, fluconazole), macrolides (erythromycin, clarithromycin), and some protease inhibitors. Watch for oversedation and QT effects when one is added.
QT-prolonging drugs
Methadone's QT risk is additive with other QT-prolonging agents: certain antiarrhythmics, some antipsychotics, some antibiotics (e.g., fluoroquinolones, macrolides), some antiemetics (e.g., ondansetron at higher doses), and others. Combine cautiously, correct electrolytes, and check ECGs when stacking QT risk.
Management strategy
- Before adding any drug, ask two questions: does it depress respiration? Does it change methadone's level or the QT?
- When starting an inducer, anticipate withdrawal and be ready to raise the dose. When starting an inhibitor, anticipate sedation/QT and monitor closely.
- Keep an updated medication list and coordinate with the OTP so changes aren't missed.
Part 8: Special Populations
Pregnancy
Methadone has the longest track record of any OUD medication in pregnancy and is a well-established standard of care. The governing principle: untreated OUD is far more dangerous to mother and fetus than treatment, since untreated use brings overdose, withdrawal-related fetal stress, infection, and chaotic prenatal care.
- Do not detoxify during pregnancy as a default. Maintenance is preferred; withdrawal management carries relapse and fetal risk.
- Pharmacokinetics shift in pregnancy: clearance rises and volume of distribution expands, especially in the third trimester, so dose requirements often increase, sometimes necessitating split (twice-daily) dosing to maintain stable levels. Monitor for returning withdrawal and adjust.
- Neonatal abstinence syndrome (NAS) is expected: the neonate, physiologically dependent, may develop withdrawal (irritability, high-pitched cry, poor feeding, tremor, and in severe cases seizures) in the days after birth. NAS is anticipated, monitored, and treated by the nursery; it is not a reason to withhold maternal treatment. Coordinate delivery planning with obstetrics and pediatrics in advance.
- Buprenorphine is the main alternative and, in the MOTHER trial, was associated with less severe neonatal withdrawal; both are legitimate first-line choices, and continuity (staying on whatever is working) usually trumps switching.
Lactation
Methadone passes into breast milk in small amounts, and breastfeeding is generally considered compatible with maternal methadone and can help ease neonatal withdrawal, provided the mother is stable, not using illicit drugs, and not otherwise contraindicated. Coordinate with pediatrics and monitor the infant for sedation.
Hepatic and renal impairment
- Hepatic: methadone is hepatically metabolized; significant liver disease can alter clearance. Dose cautiously and monitor for accumulation.
- Renal: used with care; dose adjustment and closer monitoring are prudent in significant renal impairment.
Elderly
Start lower and titrate more slowly. Age brings reduced clearance, more polypharmacy (interaction and QT risk), and greater sensitivity to sedation and respiratory depression.
Low-tolerance / opioid-naïve patients
Treat with heightened caution: the induction protocol assumes meaningful opioid tolerance. In genuinely low-tolerance patients, standard OUD induction doses can be dangerous; dose conservatively and reassess frequently.
Part 9: Discontinuation
Two truths sit side by side. First, for OUD there is often no compelling reason to stop: indefinite maintenance is a legitimate, evidence-based endpoint, and the periods off medication are when patients relapse and die. Encourage patients to stay in treatment; the mortality benefit is tied to remaining on it.
Second, when discontinuation is genuinely chosen, it must be slow. As a full agonist to which the body is thoroughly adapted, methadone produces a withdrawal syndrome that is less acutely intense but far more protracted than short-acting opioids, dragging on for weeks, with lingering dysphoria, insomnia, and craving well beyond the acute phase.
- Taper gradually, in small decrements over an extended period (weeks to many months), individualized to the patient and slowed further as symptoms emerge.
- Watch for protracted withdrawal: the low-grade dysphoria, sleep disturbance, and anhedonia that persist after the acute syndrome and drive relapse.
- Relapse risk during and after a taper is high; intensify psychosocial support, and be ready to stop the taper or return to maintenance rather than push a patient off the drug and into relapse.
- Some patients transition to buprenorphine or naltrexone rather than to nothing; consider whether a switch, not a stop, is the real goal.
"Off medication" is not the same as "recovered." The safest place for many OUD patients is on an effective dose. Don't taper on a schedule; taper on a patient, and only when they genuinely want it and are stable enough to weather it.
Part 10: Methadone vs Buprenorphine vs Naltrexone
All three treat OUD; they are not interchangeable, and the choice is a clinical negotiation with the patient's life.
| Feature | Methadone | Buprenorphine | Naltrexone |
|---|---|---|---|
| Mechanism | Full mu agonist | Partial mu agonist (ceiling) | Mu antagonist |
| Where prescribed (OUD) | Certified OTP only; daily observed dosing, take-homes earned | Office-based; any DEA-registered clinician | Office-based |
| Respiratory safety | No ceiling, dose-dependent depression | Ceiling effect, safer profile | No respiratory depression (antagonist) |
| Induction hurdle | Slow, accumulation risk; the danger is week 1 | Must wait for withdrawal (COWS ≥8–10) or risk precipitated withdrawal | Requires 7–10 day opioid-free washout first |
| Craving/tolerance coverage | Strongest for high-tolerance, severe OUD | Excellent for most; may not suffice at the ceiling for the most severe | Blocks reward but doesn't treat withdrawal/craving directly |
| Retention | High | High | Lower (real-world weakness) |
| Diversion/abuse potential | Higher (full agonist) | Lower (partial; naloxone co-formulation) | None (antagonist) |
| QT concern | Yes, dose-dependent | Minimal | None |
| Best-fit patient | Severe/long-standing OUD, high tolerance, buprenorphine failures, pregnancy, those helped by clinic structure | Most patients wanting office-based care and independence | Highly motivated, antagonist-preferring, can complete washout |
When methadone is specifically preferred: more severe or higher-tolerance OUD (including heavy fentanyl use); prior buprenorphine failure or inability to tolerate the buprenorphine transition; a patient who benefits from the structure of daily observed dosing; and pregnancy, given the depth of the safety record.
When to lean the other way: buprenorphine for its respiratory ceiling and office-based convenience in most patients; naltrexone for the motivated patient who wants a non-agonist path and can complete the washout.
Retention is survival. Pick the agent the patient will stay on. A "safer" drug the patient abandons is more dangerous than methadone they keep taking.
Mechanism: The Short Version
Methadone is a full agonist at the mu-opioid receptor (with additional, clinically secondary NMDA-receptor antagonism that may contribute to analgesia and to its utility in tolerant patients). By fully and continuously occupying mu receptors, a stable daily dose:
- Prevents withdrawal across the full dosing interval,
- Suppresses craving, and
- Blunts the reward of illicit opioids through tolerance and cross-occupancy.
Its defining pharmacokinetic feature, a long, variable half-life (~24–36 hours, sometimes longer) with a much shorter duration of analgesic effect, is simultaneously its therapeutic strength (once-daily dosing that holds a patient stable) and its central danger (accumulation to a delayed peak during induction). Everything clinically important about methadone flows from that single fact.
Bedside Cheat Sheet
Induction (the dangerous window)
- Day 1: 10–30 mg (federal caps: 30 mg single / 40 mg first-day total)
- Titrate slowly thereafter: on the order of 5–10 mg every 3–5 days
- Steady state takes ~5+ days: today's effect reflects a dose from days ago
- Titrate to the trough, not the peak. Suppress severe withdrawal; don't chase full comfort on day 1
- Typical stabilizing range ~60–120 mg/day, reached over weeks
The signature danger
- Most induction deaths occur days 3–5, not day 1: delayed, cumulative respiratory depression, often overnight
- Sedation = too much drug accumulating. Hold or lower; never increase into sedation
- Never restart at the old dose after a gap: tolerance falls fast; re-induct low
- Overdose is the opioid triad, but delayed and prolonged. Naloxone works but methadone outlasts it: expect re-narcotization; prolonged observation, repeat/infuse naloxone
Cardiac
- Baseline ECG (and repeat as dose rises, esp. >100 mg/day)
- QTc <450 reassuring; 450–500 fix K⁺/Mg²⁺ and monitor; >500 reduce dose, address contributors, or consider buprenorphine
Interactions (know these cold)
- Benzodiazepines / alcohol / other CNS depressants are the black-box, potentially fatal combination. Counsel hard; don't reflexively withhold treatment (harm-reduction logic)
- CYP3A4 inducers (rifampin, carbamazepine, phenytoin, some ARVs, St. John's wort) lower levels and risk withdrawal
- CYP3A4 inhibitors (azoles, macrolides, some protease inhibitors) raise levels and risk sedation/QT
- Additive QT with other QT-prolonging drugs
Special populations
- Pregnancy: established standard; requirements often rise (may need BID); expect and treat NAS; don't detox by default
- Lactation: small milk levels; generally compatible if mother stable
- Elderly / low tolerance / hepatic disease: start lower, go slower, watch harder
Don't forget
- Constipation doesn't remit: start a bowel regimen early (osmotic + stimulant, not psyllium)
- Hypogonadism is common and missed; ask about it
- Discontinuation: maintenance is a valid endpoint; if stopping, taper slowly; withdrawal is less intense but more protracted
- Retention is survival: keep the patient in treatment
Methadone asks more of the prescriber than almost any other drug in medicine: a certified program, a baseline ECG, a slow and vigilant induction, a working knowledge of hepatic interactions, and the discipline to titrate to a plateau you cannot yet see. In exchange it offers something few interventions in any specialty can match: a roughly halved risk of death for people with a lethal disease. Its dangers are real but narrow: they live almost entirely in the first two weeks, and they yield almost entirely to patience. Respect the pharmacokinetics, screen the heart, hammer the sedative warning, and keep patients in treatment, and methadone remains, six decades on, one of the most life-saving tools we have.